Olema Pharmaceuticals, Inc. — Investor Relations & Filings
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. The company concentrates on endocrine-driven diseases, with a primary emphasis on breast cancer. Its lead product candidate, palazestrant (OP-1250), is an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). Palazestrant is under investigation in clinical trials as a potential treatment for patients with ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is advancing a pipeline of drug candidates with the goal of developing improved therapeutic options for cancer patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Director's Dealing 2021 | 2021-12-03 | English | |
| AMENDMENT NO. 1 TO THE SCHEDULE 13D | 2021-12-02 | English | |
| Director's Dealing 2021 | 2021-12-01 | English | |
| Director's Dealing 2021 | 2021-11-12 | English | |
| 10-Q | 2021-11-10 | English | |
| 8-K | 2021-11-10 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2021
15 filings
| |||||
| 13131311 | Director's Dealing 2021 | 2021-12-03 | English | ||
| 13131312 | AMENDMENT NO. 1 TO THE SCHEDULE 13D | 2021-12-02 | English | ||
| 13131313 | Director's Dealing 2021 | 2021-12-01 | English | ||
| 13131314 | Director's Dealing 2021 | 2021-11-12 | English | ||
| 13131316 | 10-Q | 2021-11-10 | English | ||
| 13131315 | 8-K | 2021-11-10 | English | ||
| 13131317 | Director's Dealing 2021 | 2021-10-21 | English | ||
| 13131318 | Director's Dealing 2021 | 2021-10-16 | English | ||
| 13131319 | Director's Dealing 2021 | 2021-10-13 | English | ||
| 13131320 | Director's Dealing 2021 | 2021-09-30 | English | ||
| 13131322 | Director's Dealing 2021 | 2021-09-22 | English | ||
| 13131323 | Director's Dealing 2021 | 2021-09-14 | English | ||
| 13131324 | Director's Dealing 2021 | 2021-09-09 | English | ||
| 13131325 | Director's Dealing 2021 | 2021-09-03 | English | ||
| 13131326 | Director's Dealing 2021 | 2021-08-21 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Olema Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32591/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32591 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32591 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32591 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32591}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Olema Pharmaceuticals, Inc. (id: 32591)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.